









Markets
/
Stocks
/
nasdaq-iclr
/

ICON PLC

ICLR

150.590USD

+5.200+3.58%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

11.50BMarket Cap

20.17P/E TTM



ICON PLC

150.590

+5.200+3.58%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of ICON PLC

Currency: USD Updated: 2026-02-06

Key Insights

ICON PLC's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 37 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 205.56.In the medium term, the stock price is expected to remain stable.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

ICON PLC's Score

Industry at a Glance

Industry Ranking

37 / 392

Overall Ranking

141 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative-

ICON PLC Highlights

StrengthsRisks

ICON Public Limited Company is a healthcare intelligence and clinical research organization. The Company is engaged in providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organizations. It offers a range of specialized services to assist pharmaceutical, biotechnology and medical device companies to bring new drugs and devices to market faster. The Company's services include clinical research services, commercial positioning, consulting, early phase, strategic solutions, laboratories, language services, medical imaging, real world intelligence, site and patient solutions, COVID-19 clinical operation and decentralized and hybrid clinical solutions. It also provides its full range of clinical, consulting and commercial services across several sectors, which include biosimilars, biotechnology, government and public health solutions, medical devices and pharmaceuticals.

Industry Leader

The company's revenue leads the industry, with the latest annual revenue totaling USD 8.28B.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 8.28B.

Undervalued

The company’s latest PE is 20.17, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 81.22M shares, decreasing 16.62% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 643.00 shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 0.06.

Analyst Rating

Based on 18 analysts

Buy

Current Rating

205.563

Target Price

+41.39%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of ICON PLC is 8.85, ranking 25 out of 392 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 2.04B, representing a year-over-year increase of 0.63%, while its net profit experienced a year-over-year increase of 98.81%.

Score

Industry at a Glance

Previous score

8.85

Change



Financials

6.47

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

10.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.81

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

ICON PLC's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of ICON PLC is 5.32, ranking 380 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is 20.17, which is 126.07% below the recent high of 45.61 and 32.07% above the recent low of 13.70.

Score

Industry at a Glance

Previous score

5.32

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 37/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of ICON PLC is 7.11, ranking 309 out of 392 in the Biotechnology & Medical Research industry. The average price target is 213.50, with a high of 235.00 and a low of 172.00.

Score

Industry at a Glance

Previous score

7.11

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 18 analysts

Buy

Current Rating

205.563

Target Price

+41.39%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

ICON PLC

ICLR

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of ICON PLC is 6.78, ranking 171 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 179.64 and the support level at 132.90, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.58

Change

0.2

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-8.574

Sell

RSI(14)

28.166

Sell

STOCH(KDJ)(9,3,3)

10.644

Oversold

ATR(14)

8.546

Low Volatility

CCI(14)

-180.288

Sell

Williams %R

86.466

Oversold

TRIX(12,20)

-0.343

Sell

StochRSI(14)

29.901

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

161.118

Sell

MA10

173.344

Sell

MA20

178.154

Sell

MA50

182.162

Sell

MA100

178.141

Sell

MA200

166.034

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of ICON PLC is 10.00, ranking 1 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 106.37%, representing a quarter-over-quarter increase of 2.28%. The largest institutional shareholder is David G. Herro, holding a total of 2.34M shares, representing 3.07% of shares outstanding, with 8566.10% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Artisan Partners Limited Partnership

7.07M

-1.58%

Wellington Management Company, LLP

4.64M

+26.63%

Orbis Investment Management Ltd.

4.14M

+1132.98%

Principal Global Investors (Equity)

3.28M

+739.17%

Ninety One UK Limited

3.01M

+0.42%

Invesco Advisers, Inc.

2.85M

+12.73%

Harris Associates L.P.

Star Investors

2.34M

+43.01%

MFS Investment Management

3.18M

-7.03%

Templeton Investment Counsel, L.L.C.

2.08M

+23.14%

Ruane, Cunniff & Goldfarb L.P.

Star Investors

1.70M

-0.42%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of ICON PLC is 7.26, ranking 15 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 1.32. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.